Spark Gene Eye Therapy Pioneer Pleads: All Therapies Are Not Created Equal
This article was originally published in The Pink Sheet Daily
Executive Summary
On the rebound from a brief stock beating after the high profile failure of similar yet different therapies, Spark Therapeutics distances its gene therapy for genetic eye disorders and assures investors that all’s well in Phase III.